Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enzolytics Inc (OP:ENZC)

0.0002 -0.0001 (-33.33%)
Streaming Delayed Price Updated: 12:59 PM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,759,017
Open 0.0003
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0003
Today's Range 0.0002 - 0.0004
52wk Range 0.0002 - 0.0011
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator
Via ACCESSWIRE
News headline image
Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement
Via ACCESSWIRE

Performance

YTD
-80.0%
-80.0%
1 Month
-33.3%
-33.3%
3 Month
-33.3%
-33.3%
6 Month
-66.7%
-66.7%
1 Year
-80.0%
-80.0%

More News

Read More
News headline image
Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells
Via ACCESSWIRE
Penny Stocks to Watch August 2024: SPZI, RJDG, HIRU, AABB more inside…
Via AB Newswire
News headline image
Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications
Via ACCESSWIRE
News headline image
Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd.
Via ACCESSWIRE
News headline image
Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment
Via ACCESSWIRE
News headline image
Enzolytics, Inc. Announces Letter of Intent for Exclusive Licensing Agreement for Patented Nitric Oxide Formulation
Via ACCESSWIRE
News headline image
Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release
Via ACCESSWIRE
News headline image
Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology
Via ACCESSWIRE
Spotlight: Stocks Under One Penny Key Updates SPZI, HNRC, ENZC, HALB, BIEI
Via AB Newswire
Topics Intellectual Property
News headline image
Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment
Via ACCESSWIRE
News headline image
Enzolytics Inc. Announces Dismissal of The Dimitar Savov Lawsuit in Nevada
Via ACCESSWIRE
News headline image
Update on Formulation of New Business Strategy
Via ACCESSWIRE
News headline image
Enzolytics Announces the Signing of the Business Combination Agreement with Sagaliam Acquisition Corp (SAGA)
Via ACCESSWIRE
News headline image
Patient Population for the Clinical Trials of ITV-1 has been Established by the European Medicines Agency ("EMA")
Via ACCESSWIRE
Stocks Under 5¢ To Watch Now! HNRC, HALB, ENZC, SNNC, SPZI
Via AB Newswire
Topics Artificial Intelligence Economy
OTC Stocks to Watch in February: CLNV, HNRC, ENZC, GEVI, PBIO
Via AB Newswire
Topics Artificial Intelligence Bonds
“Exploring Market Opportunities Stocks to Watch Under 5¢ Now: CLNV, ENZC, HNRC, HALB, SPZI”
Via AB Newswire
Topics Artificial Intelligence Energy
News headline image
Enzolytics, Inc. Announces Partnership With the Khalpey AI Lab To Forge the Future of Multi-Organ Remodeling and Rejuvenation With a Strategic Focus on Longevity
Via ACCESSWIRE
Penny Stocks, Shifts in Trends, Notable Performances, and Strategic Developments, Opportunities: CLNV, HALB, SPZI, HNRC, ENZC
Via AB Newswire
Topics Bonds Economy
News headline image
Virogentics, Inc. Receives Permit for Export to Africa of the ITV-1 Immunotherapy Solidifying the Scheduled Administration of the Treatment
Via ACCESSWIRE
News headline image
Enzolytics, Inc. Files Amended December 31, 2022 OTC Report with Audited Financials and Unaudited September 30, 2023 Quarterly Disclosure
Via ACCESSWIRE
News headline image
Biogenysis, Inc. Announces Partnering with Khalpey AI Lab and Contenta, Ltd. to Incorporate AI in Microbiome Analysis to Identify Biomarkers for Use in Accurately Predicting Alzheimer's Disease Onset and Prevention.
Via ACCESSWIRE
News headline image
Biogenysis’ International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application.
Via ACCESSWIRE

Frequently Asked Questions

Is Enzolytics Inc publicly traded?
Yes, Enzolytics Inc is publicly traded.
What exchange does Enzolytics Inc trade on?
Enzolytics Inc trades on the OTC Traded
What is the ticker symbol for Enzolytics Inc?
The ticker symbol for Enzolytics Inc is ENZC on the OTC Traded
What is the current price of Enzolytics Inc?
The current price of Enzolytics Inc is 0.0002
When was Enzolytics Inc last traded?
The last trade of Enzolytics Inc was at 12/24/25 12:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.